Tositumomab and iodine -131 tositumomab (Bexxar) is a new radioimmunotherapy in development for the treatment of low-grade or transformed, low-grade non-Hodgkin’s lymphoma (NHL).
T. A. Lister
Advertisement
Articles by T. A. Lister
The chimeric monoclonal anti-CD20 antibody rituximab (Rituxan) has been shown to have clinical activity in patients with
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Clears Investigator-Initiated IND for SRN-101 in Recurrent High-Grade Glioma
2
The Evolution of Artificial Intelligence in Oncology: Impact on Trials, Workflows, and Outcomes
3
FDA Approves Relacorilant Combo in Platinum-Resistant Ovarian Cancers
4
Navigating New Horizons in Neuroendocrine Prostate Cancer
5